ClinicalTrials.gg
RecruitingNCT07182097Updated Sep 23, 2025

Fentanyl vs. Remifentanil in Laparoscopic Cholecystectomy: Effects on Bowel Function and Pain

An interventional study of Fentanyl 2 µg/kg IV bolus + 1-2 µg/kg/h infusion during anesthesia and Remifentanil 1 µg/kg IV bolus + 0.1-1 µg/kg/min infusion during anesthesia in Postoperative Bowel Function and Postoperative Pain, sponsored by Konya City Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-23.

Sponsored by Konya City Hospital · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies testing fentanyl in Pain, Postoperative — 5 open to participants now, 6 under way, none of them phase 3. Fentanyl · Pain, Postoperative.

Planned enrollment
9th of 47
106 · median 80
Started
2025
with 3 others
No phase
12 of 47
2 open now
Registered
45th of 47
by date

Among the 47 studies testing fentanyl in Pain, Postoperative, this one is the 9th largest by planned enrollment, is one of 4 that started in 2025, is one of 12 with no phase, and was the 45th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

5 of the 47 studies testing fentanyl in Pain, Postoperative are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About fentanyl

Fentanyl: first FDA approval 1968 (SUBLIMAZE PRESERVATIVE FREE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing fentanyl in Pain, Postoperative, or all of them as a file.
02

Study summary

Background: Postoperative ileus (POI) is a common complication after abdominal surgery, leading to delayed gastrointestinal recovery, prolonged hospitalization, and increased healthcare costs. Opioids, while essential for intraoperative analgesia, are known to impair bowel motility through their μ-receptor effects. Among opioids, fentanyl and remifentanil are widely used but differ in their pharmacokinetic and pharmacodynamic profiles. Remifentanil undergoes rapid metabolism, resulting in a shorter context-sensitive half-life, while fentanyl accumulates with longer infusions. Although remifentanil may theoretically have less impact on bowel recovery, its potential to induce opioid-induced hyperalgesia (OIH) and increased analgesic requirements might prolong gastrointestinal dysfunction and worsen postoperative pain outcomes.

Objective: This randomized controlled trial aims to compare the effects of intraoperative fentanyl versus remifentanil on the recovery of postoperative bowel function and pain outcomes in patients undergoing elective laparoscopic cholecystectomy.

Methods: A total of 106 patients, aged 18-65 years and classified as ASA I-II, will be randomized into two groups: Group F (fentanyl) and Group R (remifentanil). Standardized anesthesia with propofol, rocuronium, and sevoflurane will be applied. The primary endpoint is time to first flatus. Secondary endpoints include time to first defecation, tolerance of oral diet, incidence of prolonged POI, postoperative pain scores, analgesic consumption, PONV incidence, PACU and hospital length of stay, and patient satisfaction.

Significance: The findings of this study will provide clinical evidence on whether fentanyl or remifentanil is more advantageous in terms of gastrointestinal recovery and pain management following laparoscopic cholecystectomy.

03

Conditions studied

  • Postoperative Bowel Function
  • Postoperative Pain

Browse trials for

Keywords

  • postoperative pain
  • postoperative ileus
  • postoperative bowel function
  • fentanyl
  • remifentanil
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-65 years
  • (ASA) physical status I or II
  • Scheduled for elective laparoscopic cholecystectomy
  • Provided written

Exclusion criteria

Exclusion Criteria:

  • Opioid use preoperatively
  • Previous abdominal surgery
  • History of ileus or gastrointestinal disease
  • Preoperative electrolyte imbalance
  • Liver or renal failure
  • Neuromuscular or psychiatric disorders
  • Known allergy to study medications
  • Emergency surgery
  • Surgical duration exceeding 90 minutes
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
106 participants (estimated)

Study arms

  • Active comparator
    Fentanyl Group

    Patients will receive fentanyl 2 µg/kg IV bolus at induction, followed by a continuous infusion of 1-2 µg/kg/h during maintenance of anesthesia. Standard anesthesia will be provided with propofol, rocuronium, and sevoflurane.

    Drug: Fentanyl 2 µg/kg IV bolus + 1-2 µg/kg/h infusion during anesthesia

  • Active comparator
    Remifentanil Group

    Patients will receive remifentanil 1 µg/kg IV bolus at induction, followed by a continuous infusion of 0.1-1 µg/kg/min during maintenance of anesthesia. Standard anesthesia will be provided with propofol, rocuronium, and sevoflurane.

    Drug: Remifentanil 1 µg/kg IV bolus + 0.1-1 µg/kg/min infusion during anesthesia

Interventions

  • DrugFentanyl 2 µg/kg IV bolus + 1-2 µg/kg/h infusion during anesthesia

    Drug page: FentanylStudies of FentanylFentanyl pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive fentanyl 2 µg/kg IV bolus at induction, followed by a continuous infusion of 1-2 µg/kg/h during maintenance of anesthesia. Standard anesthesia will be provided with propofol, rocuronium, and sevoflurane.

  • DrugRemifentanil 1 µg/kg IV bolus + 0.1-1 µg/kg/min infusion during anesthesia

    Drug page: RemifentanilStudies of RemifentanilRemifentanil pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive remifentanil 1 µg/kg IV bolus at induction, followed by a continuous infusion of 0.1-1 µg/kg/min during maintenance of anesthesia. Standard anesthesia will be provided with propofol, rocuronium, and sevoflurane.

06

What researchers measure

Primary outcomes

  1. Time to first flatus

    Time from admission to the post-anesthesia care unit (PACU) until the first passage of flatus, recorded in hours.

    Time frame: Up to 72 hours postoperatively

Secondary outcomes

  1. Time to first defecation

    Time from postoperative care unit admission to first defecation, recorded in hours.

    Time frame: Up to 72 hours postoperatively

  2. Postoperative pain scores (NRS)

    Pain intensity assessed using Numeric Rating Scale (0-10) at 0, 2, 4, 6, 12, and 24 hours after surgery.

    Time frame: First 24 hours postoperatively

  3. Incidence of prolonged postoperative ileus

    Defined as persistence of ≥2 of the following for more than 3 days postoperatively: nausea/vomiting, absence of flatus for 24h, inability to tolerate oral diet for 24h, abdominal distension, radiological confirmation.

    Time frame: Within 7 days postoperatively

  4. Rescue analgesic consumption

    Total amount of tramadol administered for NRS ≥4.

    Time frame: First 24 hours postoperatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Niedermayer S, Heyn J, Guenther F, Kuchenhoff H, Luchting B. Remifentanil for abdominal surgery is associated with unexpectedly unfavorable outcomes. Pain. 2020 Feb;161(2):266-273. doi: 10.1097/j.pain.0000000000001713. PubMed 31592999 ↗
  • de Boer HD, Detriche O, Forget P. Opioid-related side effects: Postoperative ileus, urinary retention, nausea and vomiting, and shivering. A review of the literature. Best Pract Res Clin Anaesthesiol. 2017 Dec;31(4):499-504. doi: 10.1016/j.bpa.2017.07.002. Epub 2017 Jul 8. PubMed 29739538 ↗
  • Muller-Lissner S, Bassotti G, Coffin B, Drewes AM, Breivik H, Eisenberg E, Emmanuel A, Laroche F, Meissner W, Morlion B. Opioid-Induced Constipation and Bowel Dysfunction: A Clinical Guideline. Pain Med. 2017 Oct 1;18(10):1837-1863. doi: 10.1093/pm/pnw255. PubMed 28034973 ↗
  • Vather R, Trivedi S, Bissett I. Defining postoperative ileus: results of a systematic review and global survey. J Gastrointest Surg. 2013 May;17(5):962-72. doi: 10.1007/s11605-013-2148-y. Epub 2013 Feb 2. PubMed 23377782 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Apr 2026, 7 months after the start.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 7 months is below that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2025
First posted
Sep 19, 2025
StartActual
Sep 19, 2025
Primary completionEst.
Apr 27, 2026
CompletionEst.
Apr 30, 2026
Last update
Sep 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07182097
Lead sponsor
Konya City Hospital
Responsible party
MUSTAFA BÜYÜKCAVLAK (Specialist in Anesthesiology and Intensive Care, Konya City Hospital) — Principal investigator
First posted
Sep 19, 2025
Start date
Sep 19, 2025
Primary completion
Apr 27, 2026 (estimated)
Completion
Apr 30, 2026 (estimated)
Last update
Sep 23, 2025

Study contacts

MUSTAFA BÜYÜKCAVLAK, MD
Contact
mustafabcavlak@gmail.com
+905064733392

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fentanyl · Remifentanil

Start the discussion